Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 911-694-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1981; 01-07 to 01-29
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP lab following strict internal protocols
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- glycerol formal
- IUPAC Name:
- glycerol formal
- Details on test material:
- Purity >99%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Charles River CRCD
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Wilmington, Massachusetts
- Age at study initiation: 12 to 13 weeks
- Weight at study initiation: 217 to 281 g
- Fasting period before study: not specified
- Housing: Following identification of mating, females were housed in stainless steel cages up to 3 per cage
- Diet (e.g. ad libitum): Purina Certified Rodent Chow #5002 ad libitum
- Water (e.g. ad libitum): tap water was available ad libitum
- Acclimation period: not specified
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 72°F
- Humidity (%): not specified
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): 12-12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): fresh daily preparation prior to dosing
VEHICLE
- Amount of vehicle (if gavage): 5ml/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability and concentration of the GF dosing olutions were confirmed by chemical analysis
- Details on mating procedure:
- - Impregnation procedure: cohoused
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- Days 6 through 17 of gestation
- Frequency of treatment:
- Once daily
- Duration of test:
- Sacrifice of the females on Day 20 of gestation
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
75
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
150
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
300
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
600
Basis:
nominal conc.
- No. of animals per sex per dose:
- 25 in all treatment groups; 24 in control group
- Control animals:
- yes, concurrent no treatment
Examinations
- Maternal examinations:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: At dosing and 1 to 4 hours following dosing except on the weekends when clinical signs were recorded only at the time of dosing
BODY WEIGHT: Yes
- Time schedule for examinations: Days 0, 6, 8, 10, 12, 14, 16, 18 and 20 of gestation
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20 - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Visceral examinations: Yes: one third per litter and all dead and externally malformed fetuses
- Skeletal examinations: Yes: all per litter
- Head examinations: Yes: Heads of fetuses that were given routine visceral examination were fixed in Bouin's solution and examined by freehand serial sections - Statistics:
- Data was examined for homogeneity of variance using the Levene Test and for normality using the Wilk and Shapiro W statistic. Significance at P = 0.05 was based on analysis of variance using a least significant difference procedure; normalizing for nonparametric data when necessary. The average live fetal weight per litter was adjusted for the time of sacrifice by covariance analysis.
- Indices:
- Maternal body weight changes
Number of live fetuses per litter
Number of resorptions/number of implants per female
Number of implants/female
Number of dead fetuses/number of live fetuses
Average live fetal weight per litter
Percent preimplantation loss - Historical control data:
- Incidence of wavy ribs among rats in historical control groups is as followed:
Study A
No. Fetuses examined: 506; No. litters examined: 38; No. malformed fetuses: 14; No. litters with malformations: 6(16%)
Study B
No. Fetuses examined: 496; No. litters examined: 39; No. malformed fetuses: 20; No. litters with malformations: 10(25%)
Study C
No. Fetuses examined: 514; No. litters examined: 39; No. malformed fetuses: 18; No. litters with malformations: 6(15%)
Study D
No. Fetuses examined: 261; No. litters examined: 20; No. malformed fetuses: 6; No. litters with malformations: 6(30%)
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
There were no clinical signs of toxicity among females in any of the treatment groups.
GF had no adverse effect on maternal body weight gain.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- > 600 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
There was a significant (P ≤ 0.05) increase in the numbers of dead and resorbed fetuses and a corresponding decrease in the number of live fetuses per litter in females from the 600 mg/kg/day dosage level group. No other adverse effects on reproductive status occured in any of the remaining dosage groups. There were dose-related statistically significant (P ≤ 0.05) decreases in average live fetal weight per litter in fetuses from dams administrated 150, 300 and 600 mg/kg/day of GF. There was no adverse effect on average live fetal weight inn fetuses from the 75 mg/kg/day dosage level group. There was a treatment-related incidence of anal atresia and tail malformations among fetuses from dams administrated 300 and 600 mg/kg/day of GF, and anasarca in fetuses from the 600 mg/kg/day group. There were no treatment-related external malformations in fetuses from the 78 and 150 mg/kg/day dosage groups. Teratogenicity was evident at visceral examination as a high incidence of cardiovascular defects, primarily defects of the ventricular septum, in fetuses from the 600 mg/kg/day dosage level group. The incidence of cardiovascular malformations among fetuses in the remaining dosage groups was comparable to or less than that of the concurrent control group. At skeletal examination treatment-related malformations were limited to an increased incidence of wavy rib in fetuses from the 150, 300, and 600 mg/kg/day dosage level groups. There were 14, 46, and 63 fetuses affected with this malformation in the 150, 300, and 600 mg/kg/day dosage level groups, respectively. This same malformations was also observed in 3 fetuses from the 75 mg/kg/day dosage level group, however, tis incidence is comparable to or less than the spontaneous frequency of this malformation observed in several individual historical control groups and was not considered to be an effect of drug administration. There were dose-related delays in fetal ossification, primarily of the skull bones, vertebra, and sternebra, in fetuses from all treatment groups. The number of fetuses with the delayed ossification was most apparent in the 150, 300 and 600 mg/kg/day dosage level groups and was considered to be primarily a reflection of the decrease in average fetal weight per litter previously mentionned at these dosage levels. The slight increase in sites of delayed ossification in the 75 mg/kg/day dosage level group compared to controls was not associated with a decrease in average fetal weight but was considered to be evidence of a fetotoxic effect. This slight delay in ossification is not a teratogenic effect since delays in ossifiction of this type are frequently observed in control fetuses, are transient, and result in no permanent skeletal alterations.
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 75 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
- Dose descriptor:
- NOAEL
- Effect level:
- 75 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: fetotoxicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Glycerol formal is foetotoxic and teratogenic in rats at dose of 150, 300 and 600 mg/kg/day. A 75 mg/kg/day was not teratogenic but was fetotoxic as evidenced by an increased incidence in sites of delayed ossification compared to the concurrent control group.
- Executive summary:
An oral teratogenic study was performed in the rat in order to determine the threshold for the teratogenic effect of GF reported by Alivert et al. (1980). Female rats were treated with GF at 75, 150, 300 and 600 mg/kg/day from days 6 throught 17 of gestation.
No adverse effects were recorded on maternal body weight gain at any dose level.
There was a significant (P ≤ 0.05) increase in the numbers of dead and resorbed fetuses and a corresponding decrease in the number of live fetuses per litter in females from the 600 mg/kg/day dosage level group. No other adverse effects on reproductive status occured in any of the remaining dosage groups. There were dose-related statistically significant (P ≤ 0.05) decreases in average live fetal weight per litter in fetuses from dams administrated 150, 300 and 600 mg/kg/day of GF. There was no adverse effect on average live fetal weight inn fetuses from the 75 mg/kg/day dosage level group. There was a treatment-related incidence of anal atresia and tail malformations among fetuses from dams administrated 300 and 600 mg/kg/day of GF, and anasarca in fetuses from the 600 mg/kg/day group. There were no treatment-related external malformations in fetuses from the 78 and 150 mg/kg/day dosage groups. Teratogenicity was evident at visceral examination as a high incidence of cardiovascular defects, primarily defects of the ventricular septum, in fetuses from the 600 mg/kg/day dosage level group. The incidence of cardiovascular malformations among fetuses in the remaining dosage groups was comparable to or less than that of the concurrent control group. At skeletal examination treatment-related malformations were limited to an increased incidence of wavy rib in fetuses from the 150, 300, and 600 mg/kg/day dosage level groups. There were 14, 46, and 63 fetuses affected with this malformation in the 150, 300, and 600 mg/kg/day dosage level groups, respectively. This same malformations was also observed in 3 fetuses from the 75 mg/kg/day dosage level group, however, tis incidence is comparable to or less than the spontaneous frequency of this malformation observed in several individual historical control groups and was not considered to be an effect of drug administration. There were dose-related delays in fetal ossification, primarily of the skull bones, vertebra, and sternebra, in fetuses from all treatment groups. The number of fetuses with the delayed ossification was most apparent in the 150, 300 and 600 mg/kg/day dosage level groups and was considered to be primarily a reflection of the decrease in average fetal weight per litter previously mentionned at these dosage levels. The slight increase in sites of delayed ossification in the 75 mg/kg/day dosage level group compared to controls was not associated with a decrease in average fetal weight but was considered to be evidence of a fetotoxic effect. This slight delay in ossification is not a teratogenic effect since delays in ossifiction of this type are frequently observed in control fetuses, are transient, and result in no permanent skeletal alterations.
Glycerol formal is foetotoxic and teratogenic in rats at dose of 150, 300 and 600 mg/kg/day. A 75 mg/kg/day was not teratogenic but was fetotoxic as evidenced by an increased incidence in sites of delayed ossification compared to the concurrent control group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
